Programmed death 1 expression on HIV-specific CD4+ T cells is driven by viral replication and associated with T cell dysfunction - PubMed (original) (raw)
Comparative Study
. 2007 Aug 1;179(3):1979-87.
doi: 10.4049/jimmunol.179.3.1979.
Affiliations
- PMID: 17641065
- DOI: 10.4049/jimmunol.179.3.1979
Comparative Study
Programmed death 1 expression on HIV-specific CD4+ T cells is driven by viral replication and associated with T cell dysfunction
Michelle D'Souza et al. J Immunol. 2007.
Abstract
Functional impairment of HIV-specific CD4(+) T cells during chronic HIV infection is closely linked to viral replication and thought to be due to T cell exhaustion. Programmed death 1 (PD-1) has been linked to T cell dysfunction in chronic viral infections, and blockade of the PD-1 pathway restores HIV-specific CD4(+) and CD8(+) T cell function in HIV infection. This study extends those findings by directly examining PD-1 expression on virus-specific CD4(+) T cells. To investigate the role of PD-1 in HIV-associated CD4(+) T cell dysfunction, we measured PD-1 expression on blood and lymph node T cells from HIV-infected subjects with chronic disease. PD-1 expression was significantly higher on IFN-gamma-producing HIV-specific CD4(+) T cells compared with total or CMV-specific CD4(+) T cells in untreated HIV-infected subjects (p = 0.0001 and p < 0.0001, respectively). PD-1 expression on HIV-specific CD4(+) T cells from subjects receiving antiretroviral therapy was significantly reduced (p = 0.007), and there was a direct correlation between PD-1 expression on HIV-specific CD4(+) T cells and plasma viral load (r = 0.71; p = 0.005). PD-1 expression was significantly higher on HIV-specific T cells in the lymph node, the main site of HIV replication, compared with those in the blood (p = 0.0078). Thus, PD-1 expression on HIV-specific CD4(+) T cells is driven by persistent HIV replication, providing a potential target for enhancing the functional capacity of HIV-specific CD4(+) T cells.
Similar articles
- PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression.
Day CL, Kaufmann DE, Kiepiela P, Brown JA, Moodley ES, Reddy S, Mackey EW, Miller JD, Leslie AJ, DePierres C, Mncube Z, Duraiswamy J, Zhu B, Eichbaum Q, Altfeld M, Wherry EJ, Coovadia HM, Goulder PJ, Klenerman P, Ahmed R, Freeman GJ, Walker BD. Day CL, et al. Nature. 2006 Sep 21;443(7109):350-4. doi: 10.1038/nature05115. Epub 2006 Aug 20. Nature. 2006. PMID: 16921384 - Combined Env- and Gag-specific T cell responses in relation to programmed death-1 receptor and CD4 T cell loss rates in human immunodeficiency virus-1 infection.
Pettersen FO, Taskén K, Kvale D. Pettersen FO, et al. Clin Exp Immunol. 2010 Aug;161(2):315-23. doi: 10.1111/j.1365-2249.2010.04179.x. Epub 2010 May 10. Clin Exp Immunol. 2010. PMID: 20491784 Free PMC article. - Elevated expression levels of inhibitory receptor programmed death 1 on simian immunodeficiency virus-specific CD8 T cells during chronic infection but not after vaccination.
Velu V, Kannanganat S, Ibegbu C, Chennareddi L, Villinger F, Freeman GJ, Ahmed R, Amara RR. Velu V, et al. J Virol. 2007 Jun;81(11):5819-28. doi: 10.1128/JVI.00024-07. Epub 2007 Mar 21. J Virol. 2007. PMID: 17376899 Free PMC article. - The inhibitory co-receptors: a way to save from anergy the HIV-specific T cells.
Simone R, Piatti G, Saverino D. Simone R, et al. Curr HIV Res. 2009 May;7(3):266-72. doi: 10.2174/157016209788347949. Curr HIV Res. 2009. PMID: 19442121 Review. - Revisiting immune exhaustion during HIV infection.
Khaitan A, Unutmaz D. Khaitan A, et al. Curr HIV/AIDS Rep. 2011 Mar;8(1):4-11. doi: 10.1007/s11904-010-0066-0. Curr HIV/AIDS Rep. 2011. PMID: 21188556 Free PMC article. Review.
Cited by
- Anti-PD-1 chimeric antigen receptor T cells efficiently target SIV-infected CD4+ T cells in germinal centers.
Eichholz K, Fukazawa Y, Peterson CW, Haeseleer F, Medina M, Hoffmeister S, Duell DM, Varco-Merth BD, Dross S, Park H, Labriola CS, Axthelm MK, Murnane RD, Smedley JV, Jin L, Gong J, Rust BJ, Fuller DH, Kiem HP, Picker LJ, Okoye AA, Corey L. Eichholz K, et al. J Clin Invest. 2024 Apr 1;134(7):e169309. doi: 10.1172/JCI169309. J Clin Invest. 2024. PMID: 38557496 Free PMC article. - Safety and Immune Responses Following Anti-PD-1 Monoclonal Antibody Infusions in Healthy Persons With Human Immunodeficiency Virus on Antiretroviral Therapy.
Gay CL, Bosch RJ, McKhann A, Cha R, Morse GD, Wimbish CL, Campbell DM, Moseley KF, Hendrickx S, Messer M, Benson CA, Overton ET, Paccaly A, Jankovic V, Miller E, Tressler R, Li JZ, Kuritzkes DR, Macatangay BJC, Eron JJ, Hardy WD; A5370 Team. Gay CL, et al. Open Forum Infect Dis. 2024 Jan 11;11(3):ofad694. doi: 10.1093/ofid/ofad694. eCollection 2024 Mar. Open Forum Infect Dis. 2024. PMID: 38449916 Free PMC article. Clinical Trial. - The role of CD4+ T cells in tumor and chronic viral immune responses.
Xie L, Fang J, Yu J, Zhang W, He Z, Ye L, Wang H. Xie L, et al. MedComm (2020). 2023 Oct 10;4(5):e390. doi: 10.1002/mco2.390. eCollection 2023 Oct. MedComm (2020). 2023. PMID: 37829505 Free PMC article. Review. - Possibility of PD-1/PD-L1 Inhibitors for the Treatment of Patients with Chronic Hepatitis B Infection.
Su M, Ye T, Wu W, Shu Z, Xia Q. Su M, et al. Dig Dis. 2024;42(1):53-60. doi: 10.1159/000534535. Epub 2023 Oct 11. Dig Dis. 2024. PMID: 37820605 Free PMC article. Review. - Counteracting Immunosenescence-Which Therapeutic Strategies Are Promising?
Hieber C, Grabbe S, Bros M. Hieber C, et al. Biomolecules. 2023 Jul 6;13(7):1085. doi: 10.3390/biom13071085. Biomolecules. 2023. PMID: 37509121 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials